- In pilot study, dulaglutide reduced binge eating (BE) in patients with type 2 diabetes (T2D) and BE disorder (BED), accompanied by reductions in body weight and HbA1c.
- Glucagon-like peptide-1 analogues might be a treatment of choice in these patients.
Why this matters
- BED presence and severity as assessed by the BE Scale (BES) are associated with worse metabolic control and greater difficulty in reaching T2D treatment targets.
- Pilot open-label, prospective, controlled study of 60 patients (32 females) age ≤65 years with HbA1c between 7.5% and 9% on metformin alone, normal renal function, and BED diagnosis randomly assigned to dulaglutide 150 mg/week or gliclazide modified release 2-3 g/day.
- Funding: None disclosed.
- After 12 weeks of treatment, both groups had significant HbA1c percentage point reductions:
- −1.073 dulaglutide.
- −0.753 gliclazide.
- P=.009 between groups.
- With dulaglutide vs gliclazide, significant decreases in:
- Body weight: −4.767 vs 0.073 kg (P<.0001>
- BMI: −1.653 vs 0.040 kg/m2 (P<.0001>
- Percentage body fat mass: −1.850% vs 0.197% (P<.0001>
- BES score: −12.067 vs −0.467 points (P<.0001>
- Small sample size.
- Short duration.